Merck KGaA Total Liabilities
Merck KGaA total liabilities. Based on the latest financial reports, Merck KGaA (MRK) has total liabilities worth €22.40 Billion EUR (≈ $26.19 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Merck KGaA (MRK) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Merck KGaA (2002–2025)
Total liabilities of Merck KGaA from 2002 to 2025. This chart illustrates how Merck KGaA's total liabilities have evolved over time, based on quarterly financial data. Explore MRK long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Merck KGaA Competitors by Total Liabilities
The table below lists competitors of Merck KGaA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Global Payments Inc
NYSE:GPN
|
USA | $39.60 Billion |
|
Amadeus IT Group S.A.
MC:AMS
|
Spain | €7.17 Billion |
|
AerCap Holdings NV
NYSE:AER
|
USA | $52.77 Billion |
|
Loews Corp
NYSE:L
|
USA | $67.20 Billion |
|
CRRC Corp Ltd Class A
SHG:601766
|
China | CN¥325.65 Billion |
|
Geely Automobile Holdings Limited
F:GRUA
|
Germany | €182.01 Billion |
|
Hindalco Industries Limited
NSE:HINDALCO
|
India | Rs1.62 Trillion |
|
Zomato Limited
NSE:ZOMATO
|
India | Rs38.94 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Merck KGaA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Merck KGaA (MRK) total assets.
Liquidity & Leverage Metrics
Merck KGaA Total Liabilities Ratios Explained
Merck KGaA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Merck KGaA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Merck KGaA (2002–2025)
The table below shows the annual total liabilities of Merck KGaA from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €23.44 Billion ≈ $27.40 Billion |
+8.62% |
| 2024-12-31 | €21.58 Billion ≈ $25.23 Billion |
-0.74% |
| 2023-12-31 | €21.74 Billion ≈ $25.42 Billion |
-3.47% |
| 2022-12-31 | €22.52 Billion ≈ $26.33 Billion |
-5.95% |
| 2021-12-31 | €23.95 Billion ≈ $28.00 Billion |
-3.36% |
| 2020-12-31 | €24.78 Billion ≈ $28.97 Billion |
-4.32% |
| 2019-12-31 | €25.90 Billion ≈ $30.28 Billion |
+31.76% |
| 2018-12-31 | €19.66 Billion ≈ $22.98 Billion |
-8.81% |
| 2017-12-31 | €21.55 Billion ≈ $25.20 Billion |
-10.93% |
| 2016-12-31 | €24.20 Billion ≈ $28.29 Billion |
-3.78% |
| 2015-12-31 | €25.15 Billion ≈ $29.41 Billion |
+77.01% |
| 2014-12-31 | €14.21 Billion ≈ $16.61 Billion |
+45.74% |
| 2013-12-31 | €9.75 Billion ≈ $11.40 Billion |
-13.17% |
| 2012-12-31 | €11.23 Billion ≈ $13.13 Billion |
-3.42% |
| 2011-12-31 | €11.63 Billion ≈ $13.59 Billion |
-3.24% |
| 2010-12-31 | €12.02 Billion ≈ $14.05 Billion |
+66.91% |
| 2009-12-31 | €7.20 Billion ≈ $8.42 Billion |
+19.50% |
| 2008-12-31 | €6.02 Billion ≈ $7.04 Billion |
-3.38% |
| 2007-12-31 | €6.23 Billion ≈ $7.29 Billion |
+45.16% |
| 2006-12-31 | €4.30 Billion ≈ $5.02 Billion |
+8.69% |
| 2005-12-31 | €3.95 Billion ≈ $4.62 Billion |
+39.77% |
| 2004-12-31 | €2.83 Billion ≈ $3.31 Billion |
-38.79% |
| 2003-12-31 | €4.62 Billion ≈ $5.40 Billion |
-15.36% |
| 2002-12-31 | €5.46 Billion ≈ $6.38 Billion |
-- |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for re… Read more